2024 World Conference on Lung Cancer (WCLC) - Posters-P3.13C.03 Basal Circulating Leukocyte-Platelet Complexes and PD-L1 Expression on Circulating Cells in Patients with Advanced SCLC

P3.13C.03 Basal Circulating Leukocyte-Platelet Complexes and PD-L1 Expression on Circulating Cells in Patients with Advanced SCLC

Back to course

Pdf Summary

The study focused on evaluating the basal levels of leukocyte-platelet complexes and PD-L1 expression on circulating cells in patients with extensive-stage small-cell lung cancer (ES-SCLC). These factors may influence the effectiveness of first-line treatment comprising durvalumab, platinum, and etoposide.<br /><br />Historically, the prognosis for patients with ES-SCLC remains poor, and determining PD-L1 expression via immunohistochemistry (IHC) in tumor tissues does not fully identify patients who might benefit most from such treatments. Hence, the researchers aimed to look at systemic markers, such as circulating PD-L1 levels, leukocyte interactions, and platelet activation, which could provide additional insights.<br /><br />The study involved 41 patients from the NCT04712903 trial, whose blood samples were analyzed through flow cytometry, and they were compared with healthy donors (N=22). Results indicated significantly higher percentages of circulating PD-L1 leukocytes, PD-L1 platelets, and activated platelets in ES-SCLC patients compared to healthy individuals before beginning the durvalumab-platinum-etoposide treatment. However, no significant differences were found in the circulating leukocyte-platelet complexes or PD-L1 levels on neutrophils between patients and healthy donors.<br /><br />The data suggest potential systemic biomarkers, beyond tumor-specific PD-L1, that could help forecast treatment outcomes and guide therapy in ES-SCLC patients. Further research could explore the role of these systemic markers in therapy response and prognosis, potentially leading to more personalized treatment approaches. The research was sponsored by AstraZeneca Spain and included contributions from multiple hospitals and research institutions across Spain.

Asset Subtitle

Margarita Majem

Meta Tag

Speaker Margarita Majem

Topic SCLC & Neuroendocrine Tumors

Keywords

leukocyte-platelet complexes

PD-L1 expression

extensive-stage small-cell lung cancer

ES-SCLC

durvalumab

platinum-etoposide treatment

systemic biomarkers

flow cytometry

circulating PD-L1 levels

AstraZeneca Spain